乳腺浸润性导管癌pS2基因、ER、PR、c-erbB-2与多药耐药基因表达及临床指标的相关性  

Relationship between expression of pS2, ER, PR, c-erbB-2 and multiple drug resistance in breast cancer

作　　者：梁建芳[1] 郑绘霞[1] 杨琴[1] 程彩霞[1] 白淘[1] 高建忠[1] 肖虹[1] 

机构地区：[1]山西医科大学第一临床医学院病理科,太原030001

出　　处：《山西医科大学学报》2004年第6期596-598,共3页Journal of Shanxi Medical University

基　　金：山西省自然科学基金资助项目 (0 12 0 40 )

摘　　要：目的　探讨 pS2基因、ER、PR、c erbB 2与多药耐药基因在乳腺浸润性导管癌中的表达与主要临床指标的关系。 方法　应用免疫组织化学SP方法检测pS2基因、ER、PR、c erbB 2和多药耐药基因MDR 1、GST π在 6 0例乳腺浸润性导管癌中的表达。结果　 6 0例乳腺浸润性导管癌中的阳性表达率分别为 pS2 5 5 %、ER 6 0 %、PR 5 1.6 7%、c erbB 2 4 0 %、MDR 175 %、GST π 5 3.3%。结论　乳腺癌多药耐药性的产生可能与 pS2、ER、PR的异常表达及c erbB 2的表达有关。Objective To explore the relationship between expression of pS2, ER, PR, c-erbB-2 and multiple drug resistance gene in breast cancer. Methods Using SP immunohistochemical technique, expression of pS2, ER, PR, c-erbB-2, MDR-1 and GST-π was studied in 60 patients with breast cancer. Results The positive expression rate of pS2, ER, PR, c-erbB-2,MDR-1, GST-π were 55%, 60%, 51.67%, 40%, 75%, and 53.30% respectively in 60 cases of breast cancer. Conclusion Abnormal expression of pS2, ER, PR, and c-erbB-2 are related to multiple drug resistance in breast cancer.

关 键 词：乳腺肿瘤 基因表达 基因 MDR-1 抗药性 多药 

分 类 号：R655.8[医药卫生—外科学]